Request Demo

Last update 09 Oct 2025

Fenretinide

Last update 09 Oct 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4-HPR – CerRx, 4-hydroxy(phenyl)retinamide, 4-hydroxyphenyl retinamide

+ [15]

Target

RARs

Action

agonists, stimulants

Mechanism

RARs agonists(Retinoic acid receptors agonists), Apoptosis stimulants

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesNeoplasms+ [5]

Active Indication

Post Acute COVID 19 SyndromeCOVID-19Dengue+ [10]

Inactive Indication

Acute Lymphoblastic LeukemiaAdenocarcinoma of prostateAdult Lymphoblastic Lymphoma+ [33]

Originator Organization

National Cancer Institute

Active Organization

SteroTherapeutics LLC

SciTech Development LLC

Laurent Pharmaceuticals, Inc.

+ [4]

Inactive Organization

National Cancer Institute

The University of Alabama at Birmingham

Children's Hospital Los Angeles

+ [6]

License Organization

National Institutes of Health

SteroTherapeutics LLC

Drug Highest PhasePhase 2/3

First Approval Date-

RegulationOrphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaC26H33NO2

InChIKeyAKJHMTWEGVYYSE-FXILSDISSA-N

CAS Registry65646-68-6

Clinical Trials associated with Fenretinide

NCT06922539

/ Not yet recruitingPhase 1

A Phase 1a/1b Trial in Relapsed/Refractory Small Cell Lung Cancer to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion

This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).

Start Date15 Oct 2025

Sponsor / Collaborator

SciTech Development LLC

NCT07149220

/ RecruitingPhase 1IIT

Safety and Chemopreventive Efficacy of Fenretinide Mucoadhesive System in Subjects With Premalignant Oral Intraepithelial Neoplasia (OIN) Lesions: In Conjunction With Pharmacokinetic Assessment in Healthy Subjects.

The goal of this clinical trial is to determine the effect of a mucoadhesive system that releases the vitamin A derivative, fenretinide (FMS), on precancerous surface epithelial (lining tissue inside your mouth) changes. Specifically, does application of the FMS induce specific changes: 1) reduction in the clinical size, 2) reduction in the histologic grade of precancerous changes (determined by microscopic examination), 3) reduce the nuclear LOH events (changes in copy number of key genes to prevent oral cancer).
The first part of this study entails a single FMS application to persons having their wisdom teeth removed. This study is done to confirm how long the FMS needs to remain in place to release the cancer-preventive agent.
Participants will: 1) Have the FMS applied over the impacted wisdom tooth for 15 minutes, 2) FMS is removed, saliva is collected, and blood is drawn from a vein in the arm. 3) Tissue overlying the impacted wisdom tooth is removed and analyzed.
The second, multi-FMS application entails patients who have precancerous oral surface epithelial changes. These patients will have: 1) a piece of the precancerous tissue removed (biopsy) and examined under a microscope to ensure the diagnosis. Blood is drawn from a vein in the arm., 2) One week after the biopsy, return to discuss the results. If the changes are precancerous, this person will be given FMS to apply to the site twice a day. 3) Patients return every 7 to 10 days (for a total of six weeks) for an oral exam and clinical pictures, return the FMS, and obtain new FMS for the upcoming week., 4) At week 3 (midway), blood is drawn from a vein in the arm., 5) After the six weeks of treatment, clinical pictures are obtained, blood is drawn from a vein in the arm and all of the remaining treated tissue is completely removed. The patient is securely contacted and results are discussed. 6) Approximately 6 weeks after the final surgery, patients return for a complete oral examination and clinical pictures are obtained.

Start Date01 Sep 2025

Sponsor / Collaborator

The Ohio State University

[+1]

NCT06528457

/ Active, not recruitingPhase 2

A Phase 2, Randomized, Double Blind, Placebo-Controlled Study to Examine the Prophylactic and Treatment Effects of a Single Dose Level of Oral Fenretinide in a Dengue Virus Challenge Model

This randomized, placebo controlled single center study examines the extent to which 600 mg/m2/day of orally administered ISLA101 (fenretinide), given prophylactically or therapeutically, may reduce or eliminate signs and symptoms of dengue virus (DENV) infection over 29 days following subcutaneous challenge of healthy subjects with 'Dengue 1 Live Virus Human Challenge' (DENV-1-LVHC). Humoral and cellular immune responses, both innate and adaptive, circulating virus, and changes in clinical laboratory measures will also be examined.

Start Date05 Sep 2024

Sponsor / Collaborator

Island Pharmaceuticals Ltd.

100 Clinical Results associated with Fenretinide

100 Translational Medicine associated with Fenretinide

100 Patents (Medical) associated with Fenretinide

1,260

Literatures (Medical) associated with Fenretinide

01 Dec 2025·ANALYTICAL BIOCHEMISTRY

Exploration of endoplasmic reticulum stress-related gene markers in amyotrophic lateral sclerosis: a comprehensive analysis of bioinformatics and machine learning

Review

Author: Duan, Zhengfei ; Yang, Fangjie ; Li, Xinmin ; Kong, Yuting ; Guo, Pengxue ; Lu, Jianwei ; Bi, Mengyao ; Wang, Jing ; Zhang, Yasu ; Ren, Chunlin

This study aimed to investigate potential biomarkers related to Endoplasmic reticulum (ER) stress in Amyotrophic lateral sclerosis (ALS) through a comprehensive bioinformatic approach. The gene expression profiles of ALS patients and healthy controls were downloaded from the Gene Expression Omnibus (GEO) database. ER stress-related genes were collected from the MSigDB databases and document literature. The "limma" R package was employed to detect the differentially expressed ER stress-related genes (DE-ERSGs). Three methods of machine learning were applied to select the hub DE-ERSGs. ROC curves were conducted to evaluate model performance. An external dataset was chosen to evaluate the diagnostic capability of hub genes. The CIBERSORT algorithm was used to evaluate the immune cell infiltration characteristics. Additionally, we constructed a systematic ceRNA regulatory network using Cytoscape software and predicted the possible drug candidates using the Enrichr platform. Molecular docking analysis was used to further validate the binding ability of the candidate drug molecules to the hub genes. Six hub DE-ERSGs (ABCA1, CKAP4, TOR1AIP1, MMP9, EDC4, and ALPP) were identified, and the related models performed well. These hub genes were concentrated in multiple pathways and related to various immune cells. Drugs such as nitroglycerin, diazepam, FENRETINIDE, and edaravone exhibited good binding affinity to the hub genes, indicating that they may be promising drugs for the management of ALS. This study revealed the essential role of ER stress in the pathogenesis of ALS from an integrative perspective, providing guidance for the development of new therapeutic targets and diagnostic strategies.

01 Sep 2025·Nanomedicine-Nanotechnology Biology and Medicine

4HPR nanoformulation regulates MAPKAPK3/3pK signaling to control Bax phosphorylation and mitochondrial translocation to execute apoptosis in neuroblastoma

Article

Author: Dev, Atul ; Sharma, Angela ; Karmakar, Surajit ; Choudhury, Subhasree Roy

Neuroblastoma (NB) is a neuroendocrine tumor derived from neural crest progenitor cells, commonly arising along the sympathetic nervous system, especially in the adrenal medulla. Despite therapeutic advances, the prognosis for advanced-stage NB remains poor, necessitating improved treatment options. 4HPR has demonstrated cytotoxicity in various tumors, including NB, with low systemic toxicity; however, its clinical use is restricted by poor solubility and bioavailability. To address this, we developed a human serum albumin-based nanoformulation of 4HPR using a simple desolvation method. This formulation effectively induced apoptosis in NB cells, marked by increased ROS generation, elevated Bax/Bcl-2 ratio, and enhanced cell detachment. Notably, we identified for the first time that MAPKAPK3 downregulation leads to reduced Bax phosphorylation and increased mitochondrial translocation. Co-immunoprecipitation confirmed a direct MAPKAPK3-Bax interaction, indicating MAPKAPK3 regulates Bax via phosphorylation. Our nanoformulation modulates this cross-talk, demonstrating promising translational potential as a novel therapeutic strategy for neuroblastoma.

01 Aug 2025·Current Drug Delivery

Development of Mixed Micelles for Enhancing Fenretinide Apparent Solubility and Anticancer Activity Against Neuroblastoma Cells

Article

Author: Alfei, Silvana ; Marimpietri, Danilo ; Zorzoli, Alessia ; Zuccari, Guendalina

Introduction/Objectives::

The purpose of the study was to evaluate the suitability of mixed micelles prepared with D-α-tocopheryl polyethylene glycol succinate (TPGS) and 1,2- distearoyl-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-PEG) to encapsulate the poorly soluble anticancer drug fenretinide (4-HPR).

Methods::

After assaying the solubilization ability of the surfactants by the equilibrium method, the micelles were prepared using the solvent casting technique starting from different 4-HPR:TPGS: DSPE-PEG w/w ratios. The resulting formulations were investigated for their stability under storage conditions and upon dilution, modelling the reaching of physiological concentrations after intravenous administration. The characterization of micelles included the determination of DL%, EE %, particle size distribution, Z-potential, and thermal analysis by DSC. The cytotoxicity studies were performed on HTLA-230 and SK-N-BE-2C neuroblastoma cells by the MTT essay.

Results::

The colloidal dispersions showed a mean diameter of 12 nm, negative Zeta potential, and a narrow dimensional distribution. 4-HPR was formulated in the mixed micelles with an encapsulation efficiency of 88% and with an increment of the apparent solubility of 363-fold. The 4-HPR entrapment remained stable up to the surfactants’ concentration of 2.97E-05 M. The loaded micelles exhibited a slow-release behaviour, with about 28% of the drug released after 24 h. On the most resistant SK-N-BE-2C cells, the encapsulated 4-HPR was significantly more active than free 4-HPR in reducing cell viability.

Conclusion::

Loaded micelles demonstrated their suitability as a new adjuvant tool potentially useful for the treatment of neuroblastoma.

News (Medical) associated with Fenretinide

24 Sep 2025

·www.prnewswire.com

SciTech Development Announces the Closing of Oversubscribed $5.5 Million Funding Round to Continue Cancer Clinical Trials

Investor confidence is fueled by remarkable interim clinical trial results for its drug, ST-001 nanoFenretinide™, showing 100% disease control at higher dose levels. DETROIT, Sept. 24, 2025 /PRNewswire/ -- SciTech Development, Inc., a clinical-stage oncology company advancing its innovative nanotechnology-enabled cancer drug, today announced the successful close of its Convertible Note Round #3 (CNR 3) at $5.5 million. The round, which officially closed on September 5, 2025, surpassed its original $3.0 million target by $2.5 million. The strong investor response is driven by extraordinary interim results from SciTech's lead drug candidate, ST-001 nanoFenretinide™ (ST-001), which is currently being evaluated in clinical trials for T-cell Non-Hodgkin Lymphoma (T-cell NHL) across nine prestigious cancer centers. "This has truly been a breakout year for SciTech," said Earle Holsapple, CEO of SciTech Development. "The oversubscription of our CNR 3 underscores the confidence investors place in our science, our market position, and the transformative potential of ST-001. We are deeply grateful to both new and returning investors for their belief in our mission and support as we advance into the next phase of our trials." Recent Clinical Highlights ST-001 has achieved an unprecedented 100% Disease Control Rate at the highest dose levels to date, with all patients demonstrating either stable disease, partial responses, or showing a clear trajectory toward complete responses. Several patients have already experienced confirmed partial responses, marking a critical step on the path toward potential complete responses. ST-001 nanoFenretinide has demonstrated efficacy in both early- and late-stage cancer patients, reinforcing its broad therapeutic potential. Along with this documented clinical activity at therapeutic doses, the trial has confirmed ST-001 safety, validating the strength of the underlying science behind the drug. Importantly, most patients report minimal side effects and have chosen to remain in the trial because of the positive impact on their health and quality of life. "Our new and returning investors are motivated by the exceptional interim trial results we've delivered and the proven strength of our team," said Andrew Stumpf, CFO of SciTech Development. "This investment enables us to continue to advance clinical development in both T-cell NHL and Small Cell Lung Cancer, while building a strong foundation for our future pipeline." About SciTech Development, Inc. SciTech Development is a clinical-stage pharmaceutical company committed to advancing the next generation of cancer treatment. Leveraging its proprietary nanotechnology drug-delivery platform, the company has developed ST-001 nanoFenretinide™, a first-in-class drug currently in clinical trials for T-cell Non-Hodgkin Lymphoma. With its patented design and proven potential, ST-001 may be applicable across a broad range of additional cancers, offering hope for more effective and accessible treatment options. Investor Relations For more information, contact David Schaffer at [email protected] or visit Forward-Looking Statements This release may contain forward-looking statements, which involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to factors including clinical trial outcomes, regulatory decisions, competitive developments, and funding availability. SOURCE SciTech Development, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

08 Apr 2025

·www.prnewswire.com

SciTech Development Announces 2nd FDA Approval of a Phase 1 a/b IND For ST-001. New IND Targets the Treatment of Relapsed/Refractory Small Cell Lung Cancer Following Its Previous Approval in the Treatment of T-Cell NHL

GROSSE POINTE FARMS, Mich., April 8, 2025 /PRNewswire/ -- SciTech Development, Inc., a clinical-stage oncology company pioneering innovative cancer therapeutics, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for "A Phase 1a/b Trial in Relapsed/Refractory Small Cell Lung Cancer (SCLC) to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension for Intravenous Infusion." This milestone greenlights SciTech to begin recruiting patients and initiates another Phase 1a/b clinical trial of ST-001, a novel nanoparticle drug designed to deliver fenretinide effectively to cancer cells. The FDA's approval follows a thorough safety review, with the agency stating, "We have completed our safety review of your application and have concluded that you may proceed with your proposed clinical investigation of fenretinide phospholipid suspension (ST-001) for small cell lung cancer." This decision marks a significant step forward in SciTech's mission to address unmet needs in oncology, particularly for patients with relapsed or refractory SCLC, a notoriously aggressive disease with limited treatment options. Leading the trial, as Principal Investigator, is Greg Kalemkerian, MD, a renowned thoracic oncologist at the University of Michigan. "Small cell lung cancer remains a formidable challenge with few effective therapies for patients who relapse or don't respond to initial treatment," said Dr. Kalemkerian. "ST-001 represents a promising approach, and I'm excited to oversee this trial to evaluate its safety and potential for SCLC patients who desperately need new options." ST-001 nanoFenretinide leverages SciTech's patented drug delivery platform to overcome fenretinide's historical bioavailability challenges, delivering high doses intravenously with enhanced efficacy and reduced toxicity. The Phase 1a/b trial will assess the drug's safety, pharmacology, and maximum tolerated dose, paving the way for further development in SCLC and potentially other cancers. Building on prior success in a Phase 1a trial for T-cell non-Hodgkin lymphoma - where ST-001 demonstrated favorable pharmacokinetics and early signs of efficacy - SciTech is preparing to launch the SCLC trial in Q2/3 2025. The company anticipates that this trial will further validate the drug's broad therapeutic potential. "We are thrilled about the FDA's approval of our IND for ST-001 in SCLC," said Earle T. Holsapple, CEO of SciTech Development. "This is a pivotal moment that brings us closer to offering a transformative treatment option for patients facing this devastating disease. "Our team's dedication to advancing ST-001's potential through innovative nanotechnology is showing promising results, and we're eager to see its impact in the clinic." About SciTech Development, Inc. SciTech Development, Inc., headquartered in Grosse Pointe Farms, Michigan, is a clinical-stage pharmaceutical company focused on revolutionizing cancer treatment through its proprietary drug delivery platform. ST-001 nanoFenretinide, its lead candidate, combines fenretinide with biocompatible phospholipids to target hard-to-treat cancers, offering hope to patients worldwide. For more information, please visit or contact: Media Contact: David Schaffer | +1-727-278-8188 | [email protected] Disclaimer: This press release contains forward-looking statements based on current expectations. Actual results may differ due to risks and uncertainties. SciTech undertakes no obligation to update these statements beyond legal requirements. SOURCE SciTech Development, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1IND

13 Jan 2025

·www.prnewswire.com

SciTech Development Advances to Next Stage of Clinical Trial for ST-001 nanoFenretinide

**Encouraging Data from Accelerated Trial Supports Progress for T-cell Non-Hodgkin Lymphoma.** DETROIT, Jan. 13, 2025 /PRNewswire/ -- SciTech Development, a clinical-stage pharmaceutical company specializing in oncology, is pleased to announce the initiation of the next stage of its clinical trial for their lead drug candidate, ST-001 nanoFenretinide (ST-001) . This milestone follows the successful completion of the accelerated safety and dose-escalation stage, where ST-001 demonstrated exceptional safety, tolerability, and pharmacokinetic performance. Advancing the Phase 1a Trial with Clear Clinical Objectives The continuation of the ST-001 clinical trial aims to achieve several critical clinical objectives: Confirm that ST-001 achieves previously reported clinical response rates. Determine the pharmacological profile of intravenous fenretinide delivered using SciTech's novel nanoparticle delivery system, designed for drugs with poor water solubility. Determine the recommended treatment dose (RTD) to evaluate disease activity and response rates in the follow-on Phase 1b trial and the planned trial in Small Cell Lung Cancer. "The success of our accelerated Phase 1a trial marks a pivotal milestone, driving ST-001 into the next critical stage of development," said Earle Holsapple, CEO of SciTech Development. "We are thrilled about the potential of ST-001 nanoFenretinide and its promise to transform treatment outcomes for patients battling cancers such as T-cell Non-Hodgkin Lymphoma." About ST-001 nanoFenretinide ST-001 nanoFenretinide is a patented nanoparticle IV formulation that combines the drug fenretinide with biocompatible phospholipids. This groundbreaking new investigational drug overcomes bioavailability challenges, enhances therapeutic efficacy, and minimizes toxicity in cancer patients. Powered by SciTech's advanced delivery platform, ST-001 enables rapid delivery of effective doses of fenretinide to cancer cells, marking a breakthrough in hard-to-treat cancers. Encouraging Early Results in Phase 1a Accelerated Trial During the accelerated stage of the trial, ST-001 achieved significant milestones: Patient Enrollment is Complete for the accelerated stage of the clinical trial marking a significant accomplishment for patients with this rare disease. Therapeutic Responses Observed: Patients demonstrated partial responses and stable disease, marking an important step for trial advancement. Excellent Tolerability for ST-001 across all dose levels to date. Outstanding Pharmacokinetics: The nanoparticle delivery platform overcame longstanding bioavailability challenges, ensuring efficient delivery of fenretinide to tissues. Future Direction for ST-001 nanoFenretinide Building on the success of the accelerated Phase 1a stage, the trial begins detailed evaluation of clinical activity and response rates in T-cell lymphomas. The trial is actively underway at nine renowned medical centers across the country. Click here to learn more about the locations and patient trial criteria. Additionally, a separate trial targeting Small Cell Lung Cancer utilizing ST-001 is scheduled to begin in Q2 2025. About SciTech Development, Inc. SciTech Development, Inc., headquartered in Michigan, is an oncology focused, clinical-stage pharmaceutical company led by a world-class team. SciTech is committed to developing innovative, effective, and affordable cancer therapeutics that address unmet medical needs to bring hope to patients around the globe. To learn about SciTech and our latest advancements, please visit . Read the latest Press Release announcing "Promising Preliminary Results from the Phase 1a Accelerated Trial". Company Contact: David Schaffer Investor Relations [email protected] (727) 278-8118 SOURCE SciTech Development, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1

100 Deals associated with Fenretinide

External Link

KEGG	Wiki	ATC	Drug Bank
D04162	Fenretinide	-	DB05076

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Post Acute COVID 19 Syndrome	Phase 3	Canada	Laurent Pharmaceuticals, Inc.	20 Nov 2023
COVID-19	Phase 3	United States	Laurent Pharmaceuticals, Inc.	29 Jun 2020
BRCA mutation positive Breast Cancer	Phase 3	Italy	Istituto Europeo di Oncologia Srl	01 Dec 2009
Hormone receptor positive breast cancer	Phase 3	United States	Eastern Cooperative Oncology Group	01 Oct 1995
Breast Cancer	Phase 3	-	Johnson & Johnson	-
Breast Cancer	Phase 3	-	Laurent Pharmaceuticals, Inc.	-
Dengue	Phase 2	United States	Island Pharmaceuticals Ltd.	05 Sep 2024
Cystic Fibrosis	Phase 2	United States	Laurent Pharmaceuticals, Inc.	05 Nov 2018
Cystic Fibrosis	Phase 2	Australia	Laurent Pharmaceuticals, Inc.	05 Nov 2018
Cystic Fibrosis	Phase 2	Canada	Laurent Pharmaceuticals, Inc.	05 Nov 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04234048 (PRNewswire) Manual	Phase 1	T-Cell Lymphoma	-	ST-001	ntjnxtljgu(mddtdrymxi) = earlier-than-anticipated stable disease and partial responses - one initial and one confirmed. cxxernxfmy (shpcctwwiw ) View more	Positive	03 Dec 2024
NCT03265288 (APPLAUD, CTgov)	Phase 2	Cystic Fibrosis	166	LAU-7b (LAU-7b)	ctnybcnrsq(pbrlcphynk) = jluurjkydb xjnmeyvgcn (enolgmsdia, tteehrdsiz - wfbgqerxcc) View more	-	09 Oct 2024
				Placebo oral capsule (Placebo)	ctnybcnrsq(pbrlcphynk) = vcscsrnbpe xjnmeyvgcn (enolgmsdia, dmkjygfkjn - xtacqifvxx) View more
NCT01553071 (Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies, Pubmed \| Cancer Chemother Pharmacol)	Phase 1	Advanced cancer	16	Fenretinide	jpfstwrmvl(vqplclwgzj) = akvxhmzecn fxmnnthyzj (ylkdekbzya )	Negative	01 Aug 2023
NCT03265288 (APPLAUD, Biospace) Manual	Phase 2	Cystic Fibrosis	166	LAU-7b	ebcvboabki(kbopmutwmf): difference = 1.23, P-Value = 0.0486	Positive	03 Nov 2022
				Placebo
NCT00546455 (CTgov)	Phase 2	Insulin Resistance \| Hepatitis \| Metabolic dysfunction-associated steatotic liver disease ... View more	21	Fenretinide (A- Fenretinide)	eqbkpgncyo(ovdsajpcmu) = sqxcemqyel hboazmcrdm (febfowgoci, qzzatifrjk - emzfkyrusk) View more	-	10 Feb 2021
				placebo (B-Placebo)	eqbkpgncyo(ovdsajpcmu) = hqblmsvuew hboazmcrdm (febfowgoci, wgvlbpcchd - wcklxolazz) View more
NCT00104923 (Pubmed \| Clin Cancer Res) Manual	Phase 1	Hematologic Neoplasms	29	Fenretinide	mkjdwirdoi(jroyiekfno) = twrkjpeigl xmryhcxkog (pmpjvakemu )	Positive	15 Aug 2017
				Fenretinide (patients with response-evaluable peripheral T-cell lymphomas)	fivnyhamnu(pjbivgvcxp) = jrxppxfaqp dwjjmbiqfr (zwrsfhvtvl ) View more
NCT00288067 (Pubmed \| Int J Radiat Oncol Biol Phys) Manual	Phase 1/2	Mantle-Cell Lymphoma \| B-Cell Lymphoma	32	fenretinide	ytllioyfzc(waqywcqnda) = No dose-limiting toxicities were observed. zqniuhjljg (lqerxxlxge ) View more	Positive	01 Feb 2017
				fenretinide+rituximab
NCT00080899 (CTgov)	Phase 2	Recurrent Prostate Carcinoma \| Non-metastatic prostate cancer \| Adenocarcinoma of prostate	23	N-(4-hydroxyphenyl) retinamide \[4-HPR\]	uqnncuvepv = oaactcjpuz ctgnbhkscw (qkkezyvbfa, erhkxbkipq - fhdcfioyfq) View more	-	06 Mar 2015
NCT00288067 (CTgov)	Phase 1/2	Marginal zone lymphoma recurrent \| Follicular Lymphoma \| Acute Lymphoblastic Leukemia ... View more	32	Fenretinide+Rituximab (Fenretinide and Rituximab)	ozcoeahrnm = funmfiueoy cxnkxopjxf (qtqokbmbvg, omigdntrab - xtcdzconsm) View more	-	06 Oct 2014
				Fenretinide+Rituximab (Fenretinide and Rituximab (Rituximab Naive))	nygnizwkqt = iwihqzloze kzqvhuovab (rjiglpelau, rnmwcunktz - ryqclxspkv)
NCT00295919 (N2004-04, ASCO2014)	Phase 1	Neuroblastoma	80	4-HPR/LXS oral powder	zrjcrlhftj(grprereeer) = wraradhqbv kuslhuviwb (qasaylixdc, 1.35 - 36.9+) View more	-	20 May 2014
				Ketoconazole	czouhwdcbr(kcfrjfytbw) = oloqczlcbk xtpiixhcdi (khgahhwbha, 14.6 - 22.1)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis